OverviewSuggest Edit

NexImmune is a biopharmaceutical company developing immunotherapy products based on the Artificial Immune Modulation nanotechnology platform. The company focuses on products that help cure cancer by directing T cell function to restore natural immunity.
TypePublic
Founded2011
HQGaithersburg, MD, US
Websiteneximmune.com
Overall CultureB-

Latest Updates

Employees (est.) (Jan 2021)45(+3%)
Share Price (Nov 2021)$10.7(-4%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at NexImmune

Scott Carmer

Scott Carmer

Chief Executive Officer, Director
Kristi Jones

Kristi Jones

Chief Operating Officer
John Trainer

John Trainer

Chief Financial Officer
Daniel Bednárik

Daniel Bednárik

Senior Vice President, Molecular Engineering & Protein Design
Alex Matschiner

Alex Matschiner

Vice President, Protein Process Development
Mathias Oelke

Mathias Oelke

Senior Vice President, Preclinical Immunotherapy and Head of Cell Biology
Show more

NexImmune Office Locations

NexImmune has an office in Gaithersburg
Gaithersburg, MD, US (HQ)
9119 Gaither Rd
Show all (1)

NexImmune Financials and Metrics

NexImmune Revenue

USD

Net income (Q1, 2021)

(8.5m)

EBIT (Q1, 2021)

(10.1m)

Market capitalization (12-Nov-2021)

255.2m

Closing stock price (12-Nov-2021)

10.7

Cash (31-Mar-2021)

118.1m

EV

137.1m
NexImmune's current market capitalization is $255.2 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

5.2m5.7m

R&D expense

8.0m15.2m

Operating expense total

13.2m20.9m

EBIT

(13.2m)(20.9m)
Quarterly
USDQ1, 2021

General and administrative expense

4.1m

R&D expense

6.0m

Operating expense total

10.1m
Annual
USDFY, 2018FY, 2019

Cash

426.0k9.1m

Prepaid Expenses

273.5k833.2k

Current Assets

12.3m11.0m

PP&E

1.7m2.6m
Quarterly
USDQ3, 2020Q1, 2021

Cash

2.0m118.1m

Prepaid Expenses

1.7m4.8m

Current Assets

3.8m123.0m

PP&E

2.9m3.6m
Annual
USDFY, 2018FY, 2019

Net Income

(12.8m)(20.5m)

Depreciation and Amortization

204.6k436.4k

Accounts Payable

192.0k235.1k

Cash From Operating Activities

(11.1m)(19.4m)
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

Net Income

15.4m(21.9m)(8.5m)

Depreciation and Amortization

304.7k448.1k174.3k

Accounts Payable

(5.2k)817.8k(645.8k)

Cash From Operating Activities

(14.4m)(19.2m)(11.2m)
USDFY, 2018

Financial Leverage

-0.6 x
Show all financial metrics

NexImmune Operating Metrics

Feb, 2021

Patent Applications (US)

8

Patents (Foreign)

37

Patents (US)

5

Phase I Trials Products

2
Show all operating metrics

NexImmune Cybersecurity Score

Cybersecurity ratingPremium dataset

D

67/100

SecurityScorecard logo

NexImmune Online and Social Media Presence

Embed Graph

NexImmune Company Culture

  • Overall Culture

    B-

    78/100

  • CEO Rating

    A+

    87/100

  • Compensation

    B

    78/100

Learn more on Comparably

NexImmune News and Updates

NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates

GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its fina…

NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that tw…

NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that S…

NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes

GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a colla…

NexImmune Strengthens Management Team with Key Appointments

GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that J…

NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference

GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Sc…
Show more

NexImmune Frequently Asked Questions

  • When was NexImmune founded?

    NexImmune was founded in 2011.

  • Who are NexImmune key executives?

    NexImmune's key executives are Scott Carmer, Kristi Jones and John Trainer.

  • How many employees does NexImmune have?

    NexImmune has 45 employees.

  • Who are NexImmune competitors?

    Competitors of NexImmune include Genprex, Lantern Pharma and Privo Technologies.

  • Where is NexImmune headquarters?

    NexImmune headquarters is located at 9119 Gaither Rd, Gaithersburg.

  • Where are NexImmune offices?

    NexImmune has an office in Gaithersburg.

  • How many offices does NexImmune have?

    NexImmune has 1 office.